Skip to content

Effects of different nerve block adjuvants with ropivacaine in a single-shot interscalene block for arthroscopic shoulder surgery: a prospective, randomized, controlled trial

Effects of different nerve block adjuvants with ropivacaine in a single-shot interscalene block for arthroscopic shoulder surgery: a prospective, randomized, controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072416
Enrollment
Unknown
Registered
2023-06-13
Start date
2023-06-22
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthroscopic shoulder surgery

Interventions

Control group:A control group with no specific treatment or intervention.
Intravenous dexamethasone group:Following induction, an intravenous bolus of 5 mg of dexamethasone should be administered right away.
Intravenous esketamine group:Immediately upon induction, an intravenous bolus of 0.15 mg/kg of esketamine was administered.
Intravenous esketamine and dexamethasone group:Immediately upon induction, an intravenous bolus of 0.15 mg/kg of esketamine and 5mg dexamethasone was administered.

Sponsors

The Sixth People's Hospital of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with "rotator cuff injury or adhesive shoulder capsulitis" who are scheduled for "shoulder arthroscopic rotator cuff repair or cleansing release"; 2. Age >= 18 years; 3. American Society of Anesthesiologists (ASA) physical status I-II; 4. The duration of the procedure is no more than 3 hours.

Exclusion criteria

Exclusion criteria: 1. Previous shoulder surgery or trauma; 2. Allergy or contraindications to the drugs used in the test; 3. Recent or long-term use of anticoagulant or antiplatelet aggregation drugs; 4. Patients taking sedative, analgesic and psychotropic drugs for a long time; 5. Drug or alcohol abuse; 6. Severe heart, lung, liver, kidney, coagulation function abnormalities and mental abnormalities; 7. History of spinal trauma or severe low back pain or other chronic pain; 8. Infection or damage at the puncture site; 9. Diaphragmatic paralysis, local anesthetic allergy, gastric ulcer, uncontrolled diabetes, psychiatric illness, pregnancy, severe obesity (body mass index > 35 kg/m2), inability to understand pain scores and venous patient self-controlled analgesia (PCA) instructions, and ISB failure.

Design outcomes

Primary

MeasureTime frame
Pain score difference before and after the analgesic effect of ISB had resolved at 24 hours postoperatively;Incidence of rebound pain at the surgical site;

Secondary

MeasureTime frame
The onset, durationand NRS of rebound pain;Sleep disturbance due to postoperative shoulder pain;Rest pain, activity pain and night pain at surgical site 3, 7, 15, 30 days postoperatively;Analgesic duration of ISB;Postoperative complications (postoperative nausea and vomiting, throat discomfort, psychiatric symptoms, nerve block complications);

Countries

China

Contacts

Public ContactXu Cheng

Shanghai Sixth People's Hospital

xucheng303@163.com+86 151 0213 9984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026